26 results on '"van Schooten, Jelle"'
Number of results to display per page
Search Results
2. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein
- Author
-
van Schooten, Jelle, Farokhi, Elinaz, Schorcht, Anna, van den Kerkhof, Tom L. G. M., Gao, Hongmei, van der Woude, Patricia, Burger, Judith A., Meesters, Tim G. Rijkhold, Bijl, Tom, Ghalaiyini, Riham, Turner, Hannah L., Dorning, Jessica, van Schaik, Barbera D. C., van Kampen, Antoine H. C., Labranche, Celia C., Stanfield, Robyn L., Sok, Devin, Montefiori, David C., Burton, Dennis R., Seaman, Michael S., Ozorowski, Gabriel, Wilson, Ian A., Sanders, Rogier W., Ward, Andrew B., and van Gils, Marit J.
- Published
- 2022
- Full Text
- View/download PDF
3. Immunization with germ line–targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.
- Author
-
Nelson, Ashley N., Shen, Xiaoying, Vekatayogi, Sravani, Zhang, Shiyu, Ozorowski, Gabriel, Dennis, Maria, Sewall, Leigh M., Milligan, Emma, Davis, Dominique, Cross, Kaitlyn A., Chen, Yue, van Schooten, Jelle, Eudailey, Joshua, Isaac, John, Memon, Saad, Weinbaum, Carolyn, Gao, Hongmei, Stanfield-Oakley, Sherry, Byrd, Alliyah, and Chutkan, Suni
- Subjects
AIDS vaccines ,RHESUS monkeys ,B cells ,HIV-positive persons ,BINDING sites - Abstract
Adolescents are a growing population of people living with HIV. The period between weaning and sexual debut presents a low-risk window for HIV acquisition, making early childhood an ideal time for implementing an immunization regimen. Because the elicitation of broadly neutralizing antibodies (bnAbs) is critical for an effective HIV vaccine, our goal was to assess the ability of a bnAb B cell lineage–designed HIV envelope SOSIP (protein stabilized by a disulfide bond between gp120-gp41—named "SOS"—and an isoleucine-to-proline point mutation—named "IP"—at residue 559) to induce precursor CD4 binding site (CD4bs)–targeting bnAbs in early life. Infant rhesus macaques received either a BG505 SOSIP, based on the infant BG505 transmitted/founder virus, or the CD4bs germ line–targeting BG505 SOSIP GT1.1 (n = 5 per group). Although both strategies induced durable, high-magnitude plasma autologous virus neutralization responses, only GT1.1-immunized infants (n = 3 of 5) exhibited VRC01-like CD4bs bnAb precursor development. Thus, a multidose immunization regimen with bnAb lineage–designed SOSIPs shows promise for inducing early B cell responses with the potential to mature into protective HIV bnAbs before sexual debut. Editor's summary: HIV vaccine efforts include developing immunogens that induce broadly neutralizing antibodies (bnAbs). Two studies highlight advances in inducing VRC01 class bnAbs that bind to the conserved CD4 binding site (CD4bs) epitope of the HIV envelope (Env). Caniels et al. used structure-based design to optimize a trimeric HIV Env antigen, called BG505 SOSIP GT1.1 (GT1.1). Adult nonhuman primates (NHPs) immunized with GT1.1 produced antibodies that neutralize fully glycosylated viruses by specifically binding to the CD4bs. Nelson et al. evaluated GT1.1 in infant NHPs compared with a predecessor immunogen, BG505 SOSIP. Both immunogens induced neutralizing antibodies against autologous viruses, but only infants primed with GT1.1 generated VRC01-like CD4bs bnAb precursors upon boosting with BG505 SOSIP. These findings indicate that trimeric germ line–targeting immunogens can elicit neutralizing antibodies toward conserved HIV Env epitopes. (See accompanying Research Article by Caniels et al. and accompanying Focus by Amara.) —Christiana Fogg [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site.
- Author
-
Caniels, Tom G., Medina-Ramìrez, Max, Zhang, Shiyu, Kratochvil, Sven, Xian, Yuejiao, Koo, Ja-Hyun, Derking, Ronald, Samsel, Jakob, van Schooten, Jelle, Pecetta, Simone, Lamperti, Edward, Yuan, Meng, Carrasco, María Ríos, del Moral Sánchez, Iván, Allen, Joel D., Bouhuijs, Joey H., Yasmeen, Anila, Ketas, Thomas J., Snitselaar, Jonne L., and Bijl, Tom P. L.
- Subjects
AIDS vaccines ,BINDING sites ,B cells ,VACCINE development ,IMMUNOGLOBULINS - Abstract
Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine development. Here, we describe how germline-targeting immunogen BG505 SOSIP germline trimer 1.1 (GT1.1), generated through structure-based design, engages a diverse range of VRC01-class bnAb precursors. A single immunization with GT1.1 expands CD4 binding site (CD4bs)–specific VRC01-class B cells in knock-in mice and drives VRC01-class maturation. In nonhuman primates (NHPs), GT1.1 primes CD4bs-specific neutralizing serum responses. Selected monoclonal antibodies (mAbs) isolated from GT1.1-immunized NHPs neutralize fully glycosylated BG505 virus. Two mAbs, 12C11 and 21N13, neutralize subsets of diverse heterologous neutralization-resistant viruses. High-resolution structures revealed that 21N13 targets the same conserved residues in the CD4bs as VRC01-class and CH235-class bnAbs despite its low sequence similarity (~40%), whereas mAb 12C11 binds predominantly through its heavy chain complementarity-determining region 3. These preclinical data underpin the ongoing evaluation of GT1.1 in a phase 1 clinical trial in healthy volunteers. Editor's summary: HIV vaccine efforts include developing immunogens that induce broadly neutralizing antibodies (bnAbs). Two studies highlight advances in inducing VRC01-class bnAbs that bind to the conserved CD4 binding site (CD4bs) epitope of the HIV envelope (Env). Caniels et al. used structure-based design to optimize a trimeric HIV Env antigen called BG505 SOSIP GT1.1 (GT1.1). Adult nonhuman primates (NHPs) immunized with GT1.1 produced antibodies that neutralized fully glycosylated viruses by specifically binding to the CD4bs. Nelson et al. evaluated GT1.1 in infant NHPs compared with a predecessor immunogen, BG505 SOSIP. Both immunogens induced neutralizing antibodies against autologous viruses, but only infants primed with GT1.1 generated VRC01-like CD4bs bnAb precursors upon boosting with BG505 SOSIP. These findings indicate that trimeric germline-targeting immunogens can elicit neutralizing antibodies toward conserved HIV Env epitopes. (See accompanying Research Article by Nelson et al. and accompanying Focus by Amara.) —Christiana Fogg [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
- Author
-
Maisonnasse, Pauline, Aldon, Yoann, Marc, Aurélien, Marlin, Romain, Dereuddre-Bosquet, Nathalie, Kuzmina, Natalia A., Freyn, Alec W., Snitselaar, Jonne L., Gonçalves, Antonio, Caniels, Tom G., Burger, Judith A., Poniman, Meliawati, Bontjer, Ilja, Chesnais, Virginie, Diry, Ségolène, Iershov, Anton, Ronk, Adam J., Jangra, Sonia, Rathnasinghe, Raveen, Brouwer, Philip J. M., Bijl, Tom P. L., van Schooten, Jelle, Brinkkemper, Mitch, Liu, Hejun, Yuan, Meng, Mire, Chad E., van Breemen, Mariëlle J., Contreras, Vanessa, Naninck, Thibaut, Lemaître, Julien, Kahlaoui, Nidhal, Relouzat, Francis, Chapon, Catherine, Ho Tsong Fang, Raphaël, McDanal, Charlene, Osei-Twum, Mary, St-Amant, Natalie, Gagnon, Luc, Montefiori, David C., Wilson, Ian A., Ginoux, Eric, de Bree, Godelieve J., García-Sastre, Adolfo, Schotsaert, Michael, Coughlan, Lynda, Bukreyev, Alexander, van der Werf, Sylvie, Guedj, Jérémie, Sanders, Rogier W., van Gils, Marit J., and Le Grand, Roger
- Published
- 2021
- Full Text
- View/download PDF
6. Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.
- Author
-
Nelson, Ashley N, primary, Shen, Xiaoying, additional, Venkatayogi, Sravani, additional, Zhang, Shiyu, additional, Ozorowski, Gabriel, additional, Dennis, Maria, additional, Sewall, Leigh M, additional, Milligan, Emma, additional, Davis, Dominique, additional, Cross, Kaitlyn, additional, Chen, Yue, additional, van Schooten, Jelle, additional, Eudaily, Joshua, additional, Isaac, John, additional, Memon, Saad, additional, Weinbaum, Carolyn, additional, Stanfield-Oakley, Sherry, additional, Byrd, Alliyah, additional, Chutkan, Suni, additional, Berendam, Stella, additional, Cronin, Kenneth, additional, Yasmeen, Anila, additional, Alam, S.Munir, additional, LeBranche, Celia, additional, Rogers, Kenneth, additional, Shirreff, Lisa, additional, Cupo, Albert, additional, Derking, Ronlad, additional, Villinger, Francois, additional, Klasse, Per Johan, additional, Ferrari, Guido, additional, Williams, Wilton B, additional, Hudgens, Michael G, additional, Ward, Andrew B, additional, Montefiori, David C, additional, VanRompay, Koen, additional, Wiehe, Kevin, additional, Moore, John P, additional, Sanders, Rogier W, additional, De Paris, Kristina, additional, and Permar, Sallie R, additional
- Published
- 2023
- Full Text
- View/download PDF
7. CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals
- Author
-
Gristick, Harry B., primary, Hartweger, Harald, additional, Loewe, Maximilian, additional, van Schooten, Jelle, additional, Ramos, Victor, additional, Oliveira, Thiago Y., additional, Nishimura, Yoshiaki, additional, Koranda, Nicholas S., additional, Wall, Abigail, additional, Yao, Kai-Hui, additional, Poston, Daniel, additional, Gazumyan, Anna, additional, Wiatr, Marie, additional, Horning, Marcel, additional, Keeffe, Jennifer R., additional, Hoffmann, Magnus A. G., additional, Yang, Zhi, additional, Abernathy, Morgan E., additional, Dam, Kim-Marie A., additional, Gao, Han, additional, Gnanapragasam, Priyanthi N. P., additional, Kakutani, Leesa M., additional, Pavlovitch-Bedzyk, Ana Jimena, additional, Seaman, Michael S., additional, Howarth, Mark, additional, McGuire, Andrew T., additional, Stamatatos, Leonidas, additional, Martin, Malcolm A., additional, West, Anthony P., additional, Nussenzweig, Michel C., additional, and Bjorkman, Pamela J., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Structural basis of antibodies targeting neutralizing epitopes revealed by cryoempem
- Author
-
Zhang, Shiyu, primary, Ozorowski, Gabriel, additional, Antanasijevic, Aleksandar, additional, van Schooten, Jelle, additional, Richey, Sara, additional, Copps, Jeffrey, additional, Karlsson Hedestam, Gunilla, additional, Sanders, Rogier W., additional, and Ward, Andrew, additional
- Published
- 2023
- Full Text
- View/download PDF
9. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
- Author
-
van Schooten, Jelle and van Gils, Marit J.
- Published
- 2018
- Full Text
- View/download PDF
10. Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
- Author
-
van Schooten, Jelle, primary, Schorcht, Anna, additional, Farokhi, Elinaz, additional, Umotoy, Jeffrey C., additional, Gao, Hongmei, additional, van den Kerkhof, Tom L. G. M., additional, Dorning, Jessica, additional, Rijkhold Meesters, Tim G., additional, van der Woude, Patricia, additional, Burger, Judith A., additional, Bijl, Tom, additional, Ghalaiyini, Riham, additional, Torrents de la Peña, Alba, additional, Turner, Hannah L., additional, Labranche, Celia C., additional, Stanfield, Robyn L., additional, Sok, Devin, additional, Schuitemaker, Hanneke, additional, Montefiori, David C., additional, Burton, Dennis R., additional, Ozorowski, Gabriel, additional, Seaman, Michael S., additional, Wilson, Ian A., additional, Sanders, Rogier W., additional, Ward, Andrew B., additional, and van Gils, Marit J., additional
- Published
- 2022
- Full Text
- View/download PDF
11. CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals
- Author
-
Gristick, Harry B., primary, Hartweger, Harald, additional, Loewe, Maximilian, additional, van Schooten, Jelle, additional, Ramos, Victor, additional, Oliviera, Thiago Y., additional, Nishimura, Yoshiaki, additional, Koranda, Nicholas S., additional, Wall, Abigail, additional, Yao, Kai-Hui, additional, Poston, Daniel, additional, Gazumyan, Anna, additional, Wiatr, Marie, additional, Horning, Marcel, additional, Keeffe, Jennifer R., additional, Hoffmann, Magnus A.G., additional, Yang, Zhi, additional, Abernathy, Morgan E., additional, Dam, Kim-Marie A., additional, Gao, Han, additional, Gnanapragasam, Priyanthi N.P., additional, Kakutani, Leesa M., additional, Pavlovitch-Bedzyk, Ana Jimena, additional, Seaman, Michael S., additional, Howarth, Mark, additional, McGuire, Andrew T., additional, Stamatatos, Leonidas, additional, Martin, Malcolm A., additional, West, Anthony P., additional, Nussenzweig, Michel C., additional, and Bjorkman, Pamela J., additional
- Published
- 2022
- Full Text
- View/download PDF
12. CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals
- Author
-
Gristick, Harry B., Hartweger, Harald, Loewe, Maximilian, van Schooten, Jelle, Ramos, Victor, Oliviera, Thiago Y., Nishimura, Yoshiaki, Koranda, Nicholas S., Wall, Abigail, Yao, Kai-Hui, Poston, Daniel, Gazumyan, Anna, Wiatr, Marie, Horning, Marcel, Keeffe, Jennifer R., Hoffmann, Magnus A. G., Yang, Zhi, Abernathy, Morgan E., Dam, Kim-Marie A., Gao, Han, Gnanapragasam, Priyanthi N. P., Kakutani, Leesa M., Pavlovitch-Bedzyk, Ana Jimena, Seaman, Michael S., Howarth, Mark, McGuire, Andrew T., Stamatatos, Leonidas, Martin, Malcolm A., West, Anthony P., Jr., Nussenzweig, Michel C., Bjorkman, Pamela J., Gristick, Harry B., Hartweger, Harald, Loewe, Maximilian, van Schooten, Jelle, Ramos, Victor, Oliviera, Thiago Y., Nishimura, Yoshiaki, Koranda, Nicholas S., Wall, Abigail, Yao, Kai-Hui, Poston, Daniel, Gazumyan, Anna, Wiatr, Marie, Horning, Marcel, Keeffe, Jennifer R., Hoffmann, Magnus A. G., Yang, Zhi, Abernathy, Morgan E., Dam, Kim-Marie A., Gao, Han, Gnanapragasam, Priyanthi N. P., Kakutani, Leesa M., Pavlovitch-Bedzyk, Ana Jimena, Seaman, Michael S., Howarth, Mark, McGuire, Andrew T., Stamatatos, Leonidas, Martin, Malcolm A., West, Anthony P., Jr., Nussenzweig, Michel C., and Bjorkman, Pamela J.
- Abstract
Passive transfer of broadly neutralizing anti-HIV-1 antibodies (bNAbs) protects against infection, and therefore eliciting bNAbs by vaccination is a major goal of HIV-1 vaccine efforts. bNAbs that target the CD4-binding site (CD4bs) on HIV-1 Env are among the most broadly active, but to date, responses elicited against this epitope in vaccinated animals have lacked potency and breadth. We hypothesized that CD4bs bNAbs resembling the antibody IOMA might be easier to elicit than other CD4bs antibodies that exhibit higher somatic mutation rates, a difficult-to-achieve mechanism to accommodate Env’s N276_(gp120) N-glycan, and rare 5-residue light chain complementarity determining region 3s (CDRL3s). As an initial test of this idea, we developed IOMA germline-targeting Env immunogens and evaluated a sequential immunization regimen in transgenic mice expressing germline-reverted IOMA. These mice developed CD4bs epitope-specific responses with heterologous neutralization, and cloned antibodies overcame neutralization roadblocks including accommodating the N276_(gp120) glycan, with some neutralizing selected HIV-1 strains more potently than IOMA. The immunization regimen also elicited CD4bs-specific responses in animals containing polyclonal antibody repertoires. Thus, germline-targeting of IOMA-class antibody precursors represents a potential vaccine strategy to induce CD4bs bNAbs.
- Published
- 2022
13. Fine-mapping HIV-1 antibody responses to guide vaccine design
- Author
-
van Schooten, Jelle, Sanders, Rogier W., van Gils, Marit J., Faculteit der Geneeskunde, AII - Infectious diseases, and Graduate School
- Abstract
The development of a vaccine will be essential to combat, control and eventually eradicate the human immunodeficiency virus (HIV-1) from the human population. Nearly all viral vaccines work through the induction of antibodies in serum or mucosa that neutralize the pathogen before it can establish an infection. The envelope glycoprotein (Env) of HIV-1 is the only viral component on the surface of the virus and thus the sole target for neutralizing antibodies (NAbs). The development of Env-specific broadly neutralizing antibodies (bNAbs) in a subset of HIV-1 infected individuals has demonstrated that humans can produce potent, cross-neutralizing antibodies after years of infection. However, no HIV-1 vaccine has been able to elicit such responses to date. In the last two decades, the advances in immunology and structural biology have revolutionized vaccine development, allowing the (structural) characterization of isolated monoclonal antibodies (mAbs) in complex with their cognate antigen to improve the immunogenicity and effectiveness of vaccine candidates. In this thesis, we exploited structure-based reverse vaccinology to gain insight into the molecular mechanisms behind HIV-1 Env vaccine-, and infection-induced antibody responses to improve current vaccine candidates. In the first part, we present our work that explains the absence of strong neutralization breadth in non-human primates immunized with native-like trimers derived from various HIV-1 env sequences. In the second part of the thesis, we studied the antibody-virus co-evolution in an HIV-1 infected elite neutralizer, and revealed the molecular mechanisms underlying the extraordinary serum breadth of this individual.
- Published
- 2022
14. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
- Author
-
Schorcht, Anna, primary, Cottrell, Christopher A., additional, Pugach, Pavel, additional, Ringe, Rajesh P., additional, Han, Alvin X., additional, Allen, Joel D., additional, van den Kerkhof, Tom L. G. M., additional, Seabright, Gemma E., additional, Schermer, Edith E., additional, Ketas, Thomas J., additional, Burger, Judith A., additional, van Schooten, Jelle, additional, LaBranche, Celia C., additional, Ozorowski, Gabriel, additional, de Val, Natalia, additional, Bader, Daniel L. V., additional, Schuitemaker, Hanneke, additional, Russell, Colin A., additional, Montefiori, David C., additional, van Gils, Marit J., additional, Crispin, Max, additional, Klasse, P. J., additional, Ward, Andrew B., additional, Moore, John P., additional, and Sanders, Rogier W., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates
- Author
-
van Schooten, Jelle, primary, van Haaren, Marlies M., additional, Li, Hui, additional, McCoy, Laura E., additional, Havenar-Daughton, Colin, additional, Cottrell, Christopher A., additional, Burger, Judith A., additional, van der Woude, Patricia, additional, Helgers, Leanne C., additional, Tomris, Ilhan, additional, Labranche, Celia C., additional, Montefiori, David C., additional, Ward, Andrew B., additional, Burton, Dennis R., additional, Moore, John P., additional, Sanders, Rogier W., additional, Crotty, Shane, additional, Shaw, George M., additional, and van Gils, Marit J., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- Author
-
Brouwer, Philip J.M., Brinkkemper, Mitch, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Grobben, Marloes, Claireaux, Mathieu, de Gast, Marlon, Marlin, Romain, Chesnais, Virginie, Diry, Ségolène, Allen, Joel D., Watanabe, Yasunori, Giezen, Julia M., Kerster, Gius, Turner, Hannah L., van der Straten, Karlijn, van der Linden, Cynthia A., Aldon, Yoann, Naninck, Thibaut, Bontjer, Ilja, Burger, Judith A., Poniman, Meliawati, Mykytyn, Anna Z., Okba, Nisreen M.A., Schermer, Edith E., van Breemen, Marielle J., Ravichandran, Rashmi, Caniels, Tom G., van Schooten, Jelle, Kahlaoui, Nidhal, Contreras, Vanessa, Lemaître, Julien, Chapon, Catherine, Fang, Raphaël Ho Tsong, Villaudy, Julien, Sliepen, Kwinten, van der Velden, Yme U., Haagmans, Bart L., de Bree, Godelieve J., Ginoux, Eric, Ward, Andrew B., Crispin, Max, King, Neil P., van der Werf, Sylvie, van Gils, Marit J., Le Grand, Roger, Sanders, Rogier W., Brouwer, Philip J.M., Brinkkemper, Mitch, Maisonnasse, Pauline, Dereuddre-Bosquet, Nathalie, Grobben, Marloes, Claireaux, Mathieu, de Gast, Marlon, Marlin, Romain, Chesnais, Virginie, Diry, Ségolène, Allen, Joel D., Watanabe, Yasunori, Giezen, Julia M., Kerster, Gius, Turner, Hannah L., van der Straten, Karlijn, van der Linden, Cynthia A., Aldon, Yoann, Naninck, Thibaut, Bontjer, Ilja, Burger, Judith A., Poniman, Meliawati, Mykytyn, Anna Z., Okba, Nisreen M.A., Schermer, Edith E., van Breemen, Marielle J., Ravichandran, Rashmi, Caniels, Tom G., van Schooten, Jelle, Kahlaoui, Nidhal, Contreras, Vanessa, Lemaître, Julien, Chapon, Catherine, Fang, Raphaël Ho Tsong, Villaudy, Julien, Sliepen, Kwinten, van der Velden, Yme U., Haagmans, Bart L., de Bree, Godelieve J., Ginoux, Eric, Ward, Andrew B., Crispin, Max, King, Neil P., van der Werf, Sylvie, van Gils, Marit J., Le Grand, Roger, and Sanders, Rogier W.
- Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic. Brouwer et al. present preclinical evidence in support of a COVID-19 vaccine candidate, designed as a self-assembling two-component protein nanoparticle displaying multiple copies of the SARS-CoV-2 spike protein, which induces strong neutralizing antibody responses and protects from high-dose SARS-CoV-2 challenge.
- Published
- 2021
17. Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base
- Author
-
Corrigan, Angela R., primary, Duan, Hongying, additional, Cheng, Cheng, additional, Gonelli, Christopher A., additional, Ou, Li, additional, Xu, Kai, additional, DeMouth, Megan E., additional, Geng, Hui, additional, Narpala, Sandeep, additional, O’Connell, Sarah, additional, Zhang, Baoshan, additional, Zhou, Tongqing, additional, Basappa, Manjula, additional, Boyington, Jeffrey C., additional, Chen, Steven J., additional, O’Dell, Sijy, additional, Pegu, Amarendra, additional, Stephens, Tyler, additional, Tsybovsky, Yaroslav, additional, van Schooten, Jelle, additional, Todd, John P., additional, Wang, Shuishu, additional, Doria-Rose, Nicole A., additional, Foulds, Kathryn E., additional, Koup, Richard A., additional, McDermott, Adrian B., additional, van Gils, Marit J., additional, Kwong, Peter D., additional, and Mascola, John R., additional
- Published
- 2021
- Full Text
- View/download PDF
18. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- Author
-
Brouwer, Philip J.M., primary, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Grobben, Marloes, additional, Claireaux, Mathieu, additional, de Gast, Marlon, additional, Marlin, Romain, additional, Chesnais, Virginie, additional, Diry, Ségolène, additional, Allen, Joel D., additional, Watanabe, Yasunori, additional, Giezen, Julia M., additional, Kerster, Gius, additional, Turner, Hannah L., additional, van der Straten, Karlijn, additional, van der Linden, Cynthia A., additional, Aldon, Yoann, additional, Naninck, Thibaut, additional, Bontjer, Ilja, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Mykytyn, Anna Z., additional, Okba, Nisreen M.A., additional, Schermer, Edith E., additional, van Breemen, Marielle J., additional, Ravichandran, Rashmi, additional, Caniels, Tom G., additional, van Schooten, Jelle, additional, Kahlaoui, Nidhal, additional, Contreras, Vanessa, additional, Lemaître, Julien, additional, Chapon, Catherine, additional, Fang, Raphaël Ho Tsong, additional, Villaudy, Julien, additional, Sliepen, Kwinten, additional, van der Velden, Yme U., additional, Haagmans, Bart L., additional, de Bree, Godelieve J., additional, Ginoux, Eric, additional, Ward, Andrew B., additional, Crispin, Max, additional, King, Neil P., additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Le Grand, Roger, additional, and Sanders, Rogier W., additional
- Published
- 2021
- Full Text
- View/download PDF
19. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity
- Author
-
Liu, Hejun, primary, Wu, Nicholas C., additional, Yuan, Meng, additional, Bangaru, Sandhya, additional, Torres, Jonathan L., additional, Caniels, Tom G., additional, van Schooten, Jelle, additional, Zhu, Xueyong, additional, Lee, Chang-Chun D., additional, Brouwer, Philip J.M., additional, van Gils, Marit J., additional, Sanders, Rogier W., additional, Ward, Andrew B., additional, and Wilson, Ian A., additional
- Published
- 2020
- Full Text
- View/download PDF
20. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- Author
-
Brouwer, Philip J. M., primary, Brinkkemper, Mitch, additional, Maisonnasse, Pauline, additional, Dereuddre-Bosquet, Nathalie, additional, Grobben, Marloes, additional, Claireaux, Mathieu, additional, de Gast, Marlon, additional, Marlin, Romain, additional, Chesnais, Virginie, additional, Diry, Ségolène, additional, Allen, Joel D., additional, Watanabe, Yasunori, additional, Giezen, Julia M., additional, Kerster, Gius, additional, Turner, Hannah L., additional, van der Straten, Karlijn, additional, van der Linden, Cynthia A., additional, Aldon, Yoann, additional, Naninck, Thibaut, additional, Bontjer, Ilja, additional, Burger, Judith A., additional, Poniman, Meliawati, additional, Mykytyn, Anna Z., additional, Okba, Nisreen M. A., additional, Schermer, Edith E., additional, van Breemen, Marielle J., additional, Ravichandran, Rashmi, additional, Caniels, Tom G., additional, van Schooten, Jelle, additional, Kahlaoui, Nidhal, additional, Contreras, Vanessa, additional, Lemaître, Julien, additional, Chapon, Catherine, additional, Ho Tsong Fang, Raphaël, additional, Villaudy, Julien, additional, Sliepen, Kwinten, additional, van der Velden, Yme U., additional, Haagmans, Bart L., additional, de Bree, Godelieve J., additional, Ginoux, Eric, additional, Ward, Andrew B., additional, Crispin, Max, additional, King, Neil P., additional, van der Werf, Sylvie, additional, van Gils, Marit J., additional, Grand, Roger Le, additional, and Sanders, Rogier W., additional
- Published
- 2020
- Full Text
- View/download PDF
21. Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates
- Author
-
Cottrell, Christopher A., primary, van Schooten, Jelle, additional, Bowman, Charles A., additional, Yuan, Meng, additional, Oyen, David, additional, Shin, Mia, additional, Morpurgo, Robert, additional, van der Woude, Patricia, additional, van Breemen, Mariëlle, additional, Torres, Jonathan L., additional, Patel, Raj, additional, Gross, Justin, additional, Sewall, Leigh M., additional, Copps, Jeffrey, additional, Ozorowski, Gabriel, additional, Nogal, Bartek, additional, Sok, Devin, additional, Rakasz, Eva G., additional, Labranche, Celia, additional, Vigdorovich, Vladimir, additional, Christley, Scott, additional, Carnathan, Diane G., additional, Sather, D. Noah, additional, Montefiori, David, additional, Silvestri, Guido, additional, Burton, Dennis R., additional, Moore, John P., additional, Wilson, Ian A., additional, Sanders, Rogier W., additional, Ward, Andrew B., additional, and van Gils, Marit J., additional
- Published
- 2020
- Full Text
- View/download PDF
22. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- Author
-
Brouwer, Philip J. M., primary, Caniels, Tom G., additional, van der Straten, Karlijn, additional, Snitselaar, Jonne L., additional, Aldon, Yoann, additional, Bangaru, Sandhya, additional, Torres, Jonathan L., additional, Okba, Nisreen M. A., additional, Claireaux, Mathieu, additional, Kerster, Gius, additional, Bentlage, Arthur E. H., additional, van Haaren, Marlies M., additional, Guerra, Denise, additional, Burger, Judith A., additional, Schermer, Edith E., additional, Verheul, Kirsten D., additional, van der Velde, Niels, additional, van der Kooi, Alex, additional, van Schooten, Jelle, additional, van Breemen, Mariëlle J., additional, Bijl, Tom P. L., additional, Sliepen, Kwinten, additional, Aartse, Aafke, additional, Derking, Ronald, additional, Bontjer, Ilja, additional, Kootstra, Neeltje A., additional, Wiersinga, W. Joost, additional, Vidarsson, Gestur, additional, Haagmans, Bart L., additional, Ward, Andrew B., additional, de Bree, Godelieve J., additional, Sanders, Rogier W., additional, and van Gils, Marit J., additional
- Published
- 2020
- Full Text
- View/download PDF
23. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- Author
-
Brouwer, Philip J.M., primary, Caniels, Tom G., additional, van der Straten, Karlijn, additional, Snitselaar, Jonne L., additional, Aldon, Yoann, additional, Bangaru, Sandhya, additional, Torres, Jonathan L., additional, Okba, Nisreen M.A., additional, Claireaux, Mathieu, additional, Kerster, Gius, additional, Bentlage, Arthur E.H., additional, van Haaren, Marlies M., additional, Guerra, Denise, additional, Burger, Judith A., additional, Schermer, Edith E., additional, Verheul, Kirsten D., additional, van der Velde, Niels, additional, van der Kooi, Alex, additional, van Schooten, Jelle, additional, van Breemen, Mariëlle J., additional, Bijl, Tom P. L., additional, Sliepen, Kwinten, additional, Aartse, Aafke, additional, Derking, Ronald, additional, Bontjer, Ilja, additional, Kootstra, Neeltje A., additional, Wiersinga, W. Joost, additional, Vidarsson, Gestur, additional, Haagmans, Bart L., additional, Ward, Andrew B., additional, de Bree, Godelieve J., additional, Sanders, Rogier W., additional, and van Gils, Marit J., additional
- Published
- 2020
- Full Text
- View/download PDF
24. CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals
- Author
-
Harry B. Gristick, Harald Hartweger, Maximilian Loewe, Jelle van Schooten, Victor Ramos, Thiago Y. Oliveira, Yoshiaki Nishimura, Nicholas S. Koranda, Abigail Wall, Kai-Hui Yao, Daniel Poston, Anna Gazumyan, Marie Wiatr, Marcel Horning, Jennifer R. Keeffe, Magnus A. G. Hoffmann, Zhi Yang, Morgan E. Abernathy, Kim-Marie A. Dam, Han Gao, Priyanthi N. P. Gnanapragasam, Leesa M. Kakutani, Ana Jimena Pavlovitch-Bedzyk, Michael S. Seaman, Mark Howarth, Andrew T. McGuire, Leonidas Stamatatos, Malcolm A. Martin, Anthony P. West, Michel C. Nussenzweig, Pamela J. Bjorkman, Gristick, Harry B [0000-0002-1957-2821], Hartweger, Harald [0000-0002-1118-1818], Loewe, Maximilian [0000-0003-2935-3750], van Schooten, Jelle [0000-0002-5202-355X], Ramos, Victor [0000-0001-7353-3420], Oliveira, Thiago Y [0000-0002-2654-0879], Nishimura, Yoshiaki [0000-0003-1347-2368], Wall, Abigail [0000-0001-8198-2138], Poston, Daniel [0000-0001-9900-6717], Gazumyan, Anna [0000-0002-5976-9717], Horning, Marcel [0000-0003-1468-4645], Keeffe, Jennifer R [0000-0002-5317-6398], Hoffmann, Magnus AG [0000-0003-4923-9568], Yang, Zhi [0000-0001-8680-3784], Dam, Kim-Marie A [0000-0002-1416-4757], Kakutani, Leesa M [0000-0003-3822-7449], Seaman, Michael S [0000-0001-6444-3562], Howarth, Mark [0000-0001-8870-7147], McGuire, Andrew T [0000-0003-1841-6859], Stamatatos, Leonidas [0000-0002-1106-7097], Martin, Malcolm A [0000-0003-1232-2966], West, Anthony P [0000-0003-4213-5184], Nussenzweig, Michel C [0000-0003-0592-8564], Bjorkman, Pamela J [0000-0002-2277-3990], and Apollo - University of Cambridge Repository
- Subjects
Binding Sites ,Immunology ,Animals, Wild ,General Medicine ,HIV Antibodies ,Macaca mulatta ,Antibodies, Neutralizing ,Animals, Genetically Modified ,Mice ,Epitopes ,Polysaccharides ,CD4 Antigens ,HIV-1 ,Animals ,Rabbits ,Cell Adhesion Molecules ,Broadly Neutralizing Antibodies - Abstract
Passive transfer of broadly neutralizing anti–HIV-1 antibodies (bNAbs) protects against infection, and therefore, eliciting bNAbs by vaccination is a major goal of HIV-1 vaccine efforts. bNAbs that target the CD4 binding site (CD4bs) on HIV-1 Env are among the most broadly active, but to date, responses elicited against this epitope in vaccinated animals have lacked potency and breadth. We hypothesized that CD4bs bNAbs resembling the antibody IOMA might be easier to elicit than other CD4bs antibodies that exhibit higher somatic mutation rates, a difficult-to-achieve mechanism to accommodate Env’s N276 gp120 N-glycan, and rare five-residue light chain complementarity-determining region 3. As an initial test of this idea, we developed IOMA germline–targeting Env immunogens and evaluated a sequential immunization regimen in transgenic mice expressing germline-reverted IOMA. These mice developed CD4bs epitope–specific responses with heterologous neutralization, and cloned antibodies overcame neutralization roadblocks, including accommodating the N276 gp120 glycan, with some neutralizing selected HIV-1 strains more potently than IOMA. The immunization regimen also elicited CD4bs-specific responses in mice containing polyclonal antibody repertoires as well as rabbits and rhesus macaques. Thus, germline targeting of IOMA-class antibody precursors represents a potential vaccine strategy to induce CD4bs bNAbs.
- Published
- 2023
- Full Text
- View/download PDF
25. Germline-targeting SOSIP trimer immunization elicits precursor CD4 binding-site targeting broadly neutralizing antibodies in infant macaques.
- Author
-
Nelson AN, Shen X, Vekatayogi S, Zhang S, Ozorowski G, Dennis M, Sewall LM, Milligan E, Davis D, Cross KA, Chen Y, van Schooten J, Eudailey J, Isaac J, Memon S, Weinbaum C, Stanfield-Oakley S, Byrd A, Chutkan S, Berendam S, Cronin K, Yasmeen A, Alam SM, LaBranche CC, Rogers K, Shirreff L, Cupo A, Derking R, Villinger F, Klasse PJ, Ferrari G, Williams WB, Hudgens MG, Ward AB, Montefiori DC, Van Rompay KKA, Wiehe K, Moore JP, Sanders RW, De Paris K, and Permar SR
- Abstract
A vaccine that can achieve protective immunity prior to sexual debut is critical to prevent the estimated 410,000 new HIV infections that occur yearly in adolescents. As children living with HIV can make broadly neutralizing antibody (bnAb) responses in plasma at a faster rate than adults, early childhood is an opportune window for implementation of a multi-dose HIV immunization strategy to elicit protective immunity prior to adolescence. Therefore, the goal of our study was to assess the ability of a B cell lineage-designed HIV envelope SOSIP to induce bnAbs in early life. Infant rhesus macaques (RMs) received either BG505 SOSIP or the germline-targeting BG505 GT1.1 SOSIP (n=5/group) with the 3M-052-SE adjuvant at 0, 6, and 12 weeks of age. All infant RMs were then boosted with the BG505 SOSIP at weeks 26, 52 and 78, mimicking a pediatric immunization schedule of multiple vaccine boosts within the first two years of life. Both immunization strategies induced durable, high magnitude binding antibodies and plasma autologous virus neutralization that primarily targeted the CD4-binding site (CD4bs) or C3/465 epitope. Notably, three BG505 GT1.1-immunized infants exhibited a plasma HIV neutralization signature reflective of VRC01-like CD4bs bnAb precursor development and heterologous virus neutralization. Finally, infant RMs developed precursor bnAb responses at a similar frequency to that of adult RMs receiving a similar immunization strategy. Thus, a multi-dose immunization regimen with bnAb lineage designed SOSIPs is a promising strategy for inducing protective HIV bnAb responses in childhood prior to adolescence when sexual HIV exposure risk begins., Competing Interests: Competing interests: RWS, JPM and ABW are co-inventors on a patent related to BG505 SOSIP trimers, while RWS is also an inventor on a patent related to BG505 GT1.1. SRP serves as a consultant to Moderna, Merck, Pfizer, Dynavax, Hoopika, and GSK vaccine programs for CMV, and leads sponsored research programs with Moderna, Dynavax, and Merck on CMV vaccines.
- Published
- 2023
- Full Text
- View/download PDF
26. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity.
- Author
-
Liu H, Wu NC, Yuan M, Bangaru S, Torres JL, Caniels TG, van Schooten J, Zhu X, Lee CD, Brouwer PJM, van Gils MJ, Sanders RW, Ward AB, and Wilson IA
- Abstract
Most antibodies isolated from COVID-19 patients are specific to SARS-CoV-2. COVA1-16 is a relatively rare antibody that also cross-neutralizes SARS-CoV. Here we determined a crystal structure of COVA1-16 Fab with the SARS-CoV-2 RBD, and a negative-stain EM reconstruction with the spike glycoprotein trimer, to elucidate the structural basis of its cross-reactivity. COVA1-16 binds a highly conserved epitope on the SARS-CoV-2 RBD, mainly through a long CDR H3, and competes with ACE2 binding due to steric hindrance rather than epitope overlap. COVA1-16 binds to a flexible up conformation of the RBD on the spike and relies on antibody avidity for neutralization. These findings, along with structural and functional rationale for the epitope conservation, provide a blueprint for development of more universal SARS-like coronavirus vaccines and therapies.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.